Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: In surgical and diagnostic procedures: Initially, 6-9 mg/kg/hr infused over 3-5 minutes. Alternatively, 0.5-1 mg/kg via slow injection over 1-5 minutes. Maintenance: 1.5-4.5 mg/kg/hr via infusion. Additional 10-20 mg incremental bolus inj as 1% emulsion may be given if rapid increase in the depth of sedation is required. As 1% or 2% emulsion: In intensive care setting: Induction and maintenance: 0.3-4 mg/kg/hr via infusion over 5 minutes. Rate of administration may be individualised and titrated based on desired depth of sedation.
Child: As 1% emulsion for >1 month or as 2% emulsion for >3 years: In surgical and diagnostic procedures: 1-2 mg/kg given via infusion. Dose and rate of administration is adjusted according to the required depth of sedation and clinical response. Maintenance: 1.5-9 mg/kg/hr via infusion. May be supplemented with up to 1 mg/kg via bolus inj as 1% emulsion if rapid increase of depth of sedation is required.
Elderly: As 1% or 2% emulsion: Induction: Same as adult dose. Avoid rapid bolus inj. Maintenance: 80% of adult dose. Individualise dosage according to response.

Induction and maintenance of general anaesthesia
Adult: As 1% emulsion given via IV inj or infusion or as 2% emulsion given via infusion: Induction: 40 mg every 10 seconds, titrated until clinical response is achieved. Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr continuous infusion. Alternatively, 25-50 mg intermittent bolus inj of 1% emulsion. Target-controlled infusion (TCI) delivery system may also be used based on target blood concentrations, refer to detailed product guideline.
Child: As 1% emulsion for >1 month given via infusion or intermittent bolus inj or as 2% emulsion for >3 years given via infusion: Induction: 2.5-4 mg/kg. Maintenance: 9-15 mg/kg/hr.
Elderly: Induction: 20 mg every 10 seconds until onset of induction. Maintenance: 3-6 mg/kg/hr.
Chống chỉ định
Sedation in ICU setting in children <16 years.
Thận trọng
Patient with lipid metabolism disorders such as hypertriglyceridaemia or pancreatitis, or risk of fat overload; cardiac impairment; pulmonary insufficiency or respiratory depression; increased intracranial pressure or impaired cerebral circulation; hypovolaemia, unstable haemodynamics, abnormal low vascular tone (e.g. sepsis); risk factors for PRIS (e.g. decreased oxygen delivery, sepsis, serious cerebral injury). Patient predisposed to zinc deficiency (e.g. diarrhoea, major sepsis, burns). ASA grade 3 or 4, debilitated and epileptic patient. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. Avoid abrupt discontinuation; taper infusion dose to prevent withdrawal (for prolonged infusions). Not recommended for obstetric anaesthesia including caesarean section deliveries.
Tác dụng không mong muốn
Significant: ECG effects (e.g. QT shortening/prolongation), hypertriglyceridaemia, hypotension, injection-site reaction, perioperative myoclonus (e.g. convulsions, opisthotonos), involuntary movement, Rarely, postoperative unconsciousness with or without an increase in muscle tone, anaphylaxis, hypersensitivity reactions
Cardiac disorders: Cardiac arrhythmia, low cardiac output, tachycardia.
Gastrointestinal disorders: Nausea, vomiting.
Metabolism and nutrition disorders: Respiratory acidosis.
Nervous system disorders: Headache.
Psychiatric disorders: Depression, confusion.
Respiratory, thoracic and mediastinal disorders: Cough, laryngospasm.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Hypertension.
Potentially Fatal: Propofol-related infusion syndrome (PRIS) (e.g. lactic acidosis, hyperlipidaemia, hyperkalaemia, rhabdomyolysis). Abuse and dependence.
Thông tin tư vấn bệnh nhân
This drug may impair ability to drive or operate machinery.
Chỉ số theo dõi
Monitor cardiac input, blood pressure, oxygen saturation (during monitored anaesthesia care sedation); ABG (prolonged infusions). Monitor signs and symptoms of PRIS. Monitor serum triglycerides prior to initiation of therapy for ICU sedation and every 3-7 days thereafter; zinc level after 5 days of treatment.
Quá liều
Symptoms: Cardiovascular and respiratory depression. Management: Provide artificial ventilation with oxygen for respiratory depression. Reposition patient by raising the legs and lowering the head; increase IV fluids flow rate or administering plasma expanders and pressor agents to manage cardiovascular depression.
Tương tác
Additive sedative/anaesthetic and cardiorespiratory depressant effect with other CNS depressants. Profound hypotension with rifampicin. Valproate may increase serum levels of propofol.
Tương tác với thức ăn
Enhanced sedative effect with alcohol.
Tác dụng
Description: Propofol is a short-acting, liphophilic general anaesthetic. . It is thought to produce sedative/anaesthetic effects through positive modulation of inhibitory function of the neurotransmitter GABA through the GABAA receptors and possibly reduced glutamatergic activity through NMDA receptor blockade.
Onset: 9-51 seconds (average: 30 seconds).
Duration: 3-10 minutes.
Distribution: Crosses the placenta, enters breastmilk (small amounts). Volume of distribution: 2-10 L/kg; 60 L/kg (10-day infusion). Plasma protein binding: 97-99%.
Metabolism: Metabolised in the liver to water-soluble sulfate and glucuronide conjugates.
Excretion: Via urine (Approx 88% as metabolites, 40% as glucuronide metabolite); faeces (<2%). Elimination half-life: Initial: 40 minutes; Terminal: 4-7 hours, 24-72 hours (10-day infusion).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Propofol, CID=4943, (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C. Do not freeze.
Phân loại MIMS
Thuốc gây mê-gây tê
Phân loại ATC
N01AX10 - propofol ; Belongs to the class of other general anesthetics.
Tài liệu tham khảo
Anon. Propofol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 24/05/2019.

Buckingham R (ed). Propofol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 24/05/2019.

Diprivan Emulsion for Injection (Fresenius Kabi USA, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 24/05/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Propofol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Anepol
  • Anesvan
  • Fresofol 1% MCT/LCT
  • Gobbifol
  • Plofed
  • Profol
  • Propofol 1% Kabi
  • Propofol Abbott
  • Propofol-Lipuro
  • Protovan
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in